-2%
Oteseconazole is a novel azole-class antifungal agent that inhibits the fungal enzyme 14α-demethylase (CYP51). This enzyme is vital for synthesizing ergosterol, a key component of fungal cell membranes. Inhibition of CYP51 leads to toxic sterol accumulation, compromising fungal cell integrity. The tetrazole metal-binding feature in oteseconazole ensures greater selectivity for fungal enzymes over human CYP enzymes, minimizing human side effects.
Vulcan is used to prevent recurring episodes of vulvovaginal candidiasis (RVVC) in women with a documented history of RVVC who are not of reproductive potential. If fungal culture tests are done before starting treatment, antifungal therapy may begin beforehand and should be adjusted based on the results.
Caution is advised when using Vulcan with BCRP (Breast Cancer Resistance Protein) substrates, as oteseconazole may increase their systemic exposure, raising the risk of adverse effects. Starting at the lowest effective dose of BCRP substrate drugs or reducing their dose is recommended, along with close monitoring.